Zydus Lifesciences Ltd has successfully concluded a US Food and Drug Administration (USFDA) surveillance inspection at its API Unit 1 in Ankleshwar, Gujarat. The inspection, which took place from March 10 to 14, 2025, ended with “NIL observations,” indicating that the company demonstrated full compliance with quality and manufacturing practices.
The company’s financial performance has also been strong, with a 17% year-on-year revenue growth for the third quarter (Q3FY25) standing at ₹5,269 crore. The company’s net profit for the quarter was ₹1,023 crore, a 30% increase from ₹789 crore reported in the same quarter last year. A significant portion of this profit was driven by a forex gain of ₹183 crore, compared to a mere ₹21 crore in the previous year.
The company’s US formulation sales have continued to be a major driver, contributing to close to 47% of the top line. At $285 million, US formulation sales exceeded expectations, with a 29% year-over-year increase, beating analyst expectations of $270 million. This strong performance in the US market has been a significant contributor to Zydus Lifesciences’ overall growth.
Overall, the company’s successful USFDA inspection and strong financial performance suggest that Zydus Lifesciences is well-positioned for future growth and success. The company’s commitment to quality and manufacturing practices, as well as its strong performance in the US market, make it an attractive option for investors and customers alike.